Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals

Atherosclerosis Supplements

Volumn 7, Issue 4, 2006, Pages 29-32

  Hobbs, F D Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular disease; High density lipoprotein; Primary care physician

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DRUG EFFECT; DYSLIPIDEMIA; EUROPE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

CARDIOVASCULAR DISEASES; DEVELOPED COUNTRIES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; PHYSICIANS, FAMILY; RISK; RISK FACTORS;

EID: 33746375978     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2006.05.005     Document Type: Article

References (15)

1. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 9064 (1997) 1498-1504
2. Caro J., Ward A., and O'Brien J. Lifetime costs of complications resulting from type 2 diabetes in the US. Diab Care 25 (2002) 476-481
3. Mukamal K.J., Nesto R.W., Cohen M.C., et al. Impact of diabetes on long-term survival after acute myocardial infarction. Diab Care 24 (2001) 1422-1427
4. Kannel W.B. In: Genest J., et al. (Ed). Hypertension: physiology and treatment (1977), McGraw Hill, Inc., New York, NY 888-910
5. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13 (2000) 3S-10S
6. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 45 7 (2002) S5-S12
7. Mokdad A.H., Ford E.S., Bowman B.A., et al. Diabetes trends in the US 1990-1998. Diab Care 23 (2000) 1278-1283
8. Reilly J.J., and Dorosty A.R. Epidemic of obesity in UK children. Lancet 354 (1999) 1874-1875
9. Ford E.S. Prevalence of the metabolic syndrome among US adults. JAMA 287 (2002) 356-359
10. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
12. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
13. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357 9261 (2001) 972-973
14. Calvert M.J., McManus R.J., and Freemantle N. Evaluation of the management of diabetics in general practice. Diab Med 22 Suppl 2 (2005) 87
15. Scheen A.J. VALUE: analysis of results. Lancet 364 (2004) 932-933